Versant Venture Capital — Full Portfolio
5 tracked investments · listed companies and verified rows first
858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)James Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)
BoardMonal Mehta(Director)Ali Behbahani(Director)
Board seatBradley J. BolzonClare Ozawa· per SEC Form D · $37.5M raise · filed Mar 2020
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
BiotechBasel
Sven Ante Lundberg(Executive Officer)Thomas Woiwode(Director)Pablo Cagnoni(Director)Bradley Bolzon(Director)N. Anthony Coles(Director)Kala Subramanian(Executive Officer)
Board seatBradley Bolzon· per SEC Form D · $35M raise · filed Nov 2016
Co-investorsAbingworthNew Enterprise Associates (NEA)SR One Capital Management
BiotechSan Diego, US
Petpiboon Prasit(Executive Officer, Director)
BoardClare Ozawa(Executive Officer, Director)
Board seatBradley BolzonJerel DavisThomas Woiwode· per SEC Form D · $19.1M raise · filed Dec 2015
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)Karen Flick(General Counsel)
Board seatClare OzawaThomas Woiwode· per SEC Form D · $70.1M raise · filed Sep 2021
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)
Board seatJerel DavisThomas Woiwode· per SEC Form D · $70.3M raise · filed Feb 2023
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.